MARC Record from marc_nuls

LEADER: 02667pam 22003614a 4500
001 9921547300001661
005 20150423135130.0
008 040630s2004 dcua b 001 0 eng
010 $a 2004054884
020 $a0821358480
035 $a(CSdNU)u226115-01national_inst
035 $a(OCoLC)55858680
035 $a(OCoLC)55858680
040 $aDLC$cDLC$dYDX$dOrPss
042 $apcc
043 $ad------
049 $aCNUM
050 04 $aRC606.7$b.B38 2004
082 00 $a362.196/9792061$222
245 00 $aBattling HIV/AIDS :$ba decision maker's guide to the procurement of medicines and related supplies /$cYolanda Taylor, editor.
260 $aWashington, DC :$bWorld Bank,$cc2004.
300 $axxv, 152 p. :$bill. ;$c23 cm.
504 $aIncludes bibliographical references and index.
505 0 $aChallenges in Scaling up Treatment -- The economic impact of HIV/AIDS and ART -- Estimating resource requirements -- Long-term economic effect of HIV/AIDS and other considerations -- Intellectual Property Rights: A Concise Guide -- Introduction to this concise guide -- How patents affect medicines procurement -- Least developed countries -- Developing countries -- A note on "parallel imports" -- Registration and data exclusivity -- Managing the Supply Cycle for Better Outcomes -- Who does what? -- What tasks need to be done? -- Who is already carrying out these tasks? -- Monitoring procurement results -- Product Selection, Quantification, and Quality Assurance -- Product selection -- How drugs should be selected for HIV-related treatment -- Product quantification -- Quality assurance and supplier selection -- Testing and laboratory capacity -- Procurement -- Assessing capacity -- Commodities that support the HIV/AIDS program -- Planning procurement -- Registering products -- Choosing procurement methods -- Pricing -- What determines drug prices? -- Additional price determinants in retail markets -- How can public purchasers bargain for low prices? -- Estimating Resource Requirements for AIDS Treatment -- Intellectual Property Rights: How They Affect Procurement and What Steps Can Be Taken -- HIV Test Kits and Other Diagnostics.
650 0 $aAntiretroviral agents$xPurchasing.
650 0 $aAIDS (Disease)$xChemotherapy$xEconomic aspects.
650 0 $aHIV infections$xChemotherapy$xEconomic aspects.
650 0 $aPharmaceutical industry$zDeveloping countries.
650 0 $aPharmaceutical policy$zDeveloping countries.
700 1 $aTaylor, Yolanda,$d1957-
949 $aRC 606.7 .B38 2004$i31786101833223
994 $a92$bCNU
999 $aRC 606.7 .B38 2004$wLC$c1$i31786101833223$lCIRCSTACKS$mNULS$rY$sY $tBOOK$u9/21/2004